BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Sep. 10, 2013
View Archived Issues
Phase III study of GSK-2132231A in melanoma misses first co-primary endpoint
Read More
Novartis enters into global licensing and research collaboration with Regenerex
Read More
Novartis presents new series of USP2 inhibitors
Read More
New mouse model mimics hyperargininemia
Read More
Novel TYK2 inhibitors divulged by Takeda Pharmaceuticals
Read More
iPierian secures financing to launch spin-out company
Read More
Panax ginseng extract prevents adverse cisplatin effects in vivo
Read More
New locked nucleic acid antisense oligonucleotides disclosed by U.S. team
Read More
Blood smear filipin staining speeds NP-C diagnosis
Read More
Lilly presents new mGlu2 positive allosteric modulator for the treatment of anxiety
Read More
Novel tricyclic IAP antagonists synthesized at Takeda
Read More
FDA accepts corifollitropin alfa NDA for review
Read More
Merck KGaA divulges novel protein kinase inhibitors
Read More
Oncolytics Biotech reports final tumor response data for phase II study of Reolysin
Read More
Bayer Intellectual Property patents new FGFR inhibitors
Read More
Neuren Pharmaceuticals cleared to conduct phase II NNZ-2566 trial
Read More
Debiopharm and TCG Lifesciences to develop a novel class of antibiotics
Read More
Spanish team prepares novel sigma1 receptor ligands
Read More
Chimerix begins phase III trial of brincidofovir
Read More
BL-8040 receives FDA orphan drug designation for treatment of AML
Read More
Gamida Cell reports transplantation of first patient in phase I/II study of NiCord in blood cancers
Read More
Aegerion obtains orphan drug designation in Japan for use of lomitapide in treatment of HoFH
Read More
Stem Cell Therapeutics to initiate IND-enabling program for CD47 antagonist
Read More
FDA grants orphan status to ublituximab for two non-Hodgkin's lymphoma subtypes
Read More
Neurocrine discloses results from phase IIb trial of NBI-98854 for treatment of tardive dyskinesia
Read More